Literature DB >> 23344976

Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study.

K M J A Claessen1, S R Ramautar, A M Pereira, J A Romijn, H M Kroon, M Kloppenburg, N R Biermasz.   

Abstract

Arthropathy is an invalidating complication of acromegaly. This arthropathy deteriorates radiographically despite long-term disease control. However, the clinical course and its relationship to the radiographic course are currently unknown. We aimed to investigate the clinical course of arthropathy during follow-up and its relationship to radiographic progression in long-term controlled acromegaly patients. Prospective follow-up study. We studied 58 patients (mean age 62 years, women 41 %) with controlled acromegaly for a mean of 17.6 years. Clinical progression of joint disease was defined at baseline and after 2.6 years, by the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) and Australian/Canadian Osteoarthritis Index (AUSCAN) questionnaires for lower limb and hand OA, respectively, and performance tests. Potential risk factors for progression were assessed. The clinical course of arthropathy was related to the radiographic course. On average, hand and lower limb function deteriorated during follow-up, despite large interindividual variations. Joint pain was stable over time. High levels of pain and functional impairment at baseline were related to clinical progression of hand pain and functional limitations. High baseline BMI was a risk factor for functional deterioration in the lower limb. The changes in symptoms and radiographic progression during follow-up were not related. In treated acromegaly patients, joint function deteriorates during prolonged follow-up, despite biochemical disease control, although there was interindividual variation. Clinical and radiographic course of arthropathy were not related. Therefore, in clinical practice, a combination of clinical and radiographic assessment is necessary to evaluate the course of acromegalic arthropathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23344976     DOI: 10.1007/s11102-013-0464-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  Optimum tool handle diameter for a cylinder grip.

Authors:  Joaqun L Sancho-Bru; D J Giurintano; A Pérez-González; M Vergara
Journal:  J Hand Ther       Date:  2003 Oct-Dec       Impact factor: 1.950

2.  Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.

Authors:  M J E Wassenaar; N R Biermasz; M Kloppenburg; A A van der Klaauw; J Tiemensma; J W A Smit; A M Pereira; F Roelfsema; H M Kroon; J A Romijn
Journal:  Growth Horm IGF Res       Date:  2010-03-02       Impact factor: 2.372

Review 3.  Acromegalic arthropathy and sleep apnea.

Authors:  A Barkan
Journal:  J Endocrinol       Date:  1997-10       Impact factor: 4.286

4.  Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness.

Authors:  N Bellamy; J Campbell; B Haraoui; E Gerecz-Simon; R Buchbinder; K Hobby; J C MacDermid
Journal:  Osteoarthritis Cartilage       Date:  2002-11       Impact factor: 6.576

5.  Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis.

Authors:  M J E Wassenaar; N R Biermasz; J Bijsterbosch; A M Pereira; I Meulenbelt; J W A Smit; F Roelfsema; H M Kroon; J A Romijn; M Kloppenburg
Journal:  Ann Rheum Dis       Date:  2010-12-03       Impact factor: 19.103

6.  The LMS method for constructing normalized growth standards.

Authors:  T J Cole
Journal:  Eur J Clin Nutr       Date:  1990-01       Impact factor: 4.016

7.  Atlas of individual radiographic features in osteoarthritis.

Authors:  R D Altman; M Hochberg; W A Murphy; F Wolfe; M Lequesne
Journal:  Osteoarthritis Cartilage       Date:  1995-09       Impact factor: 6.576

Review 8.  Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change.

Authors:  K Bruynesteyn; M Boers; P Kostense; S van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-07-29       Impact factor: 19.103

9.  Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas.

Authors:  Agatha A van der Klaauw; Marleen Kars; Nienke R Biermasz; Ferdinand Roelfsema; Olaf M Dekkers; Eleonora P Corssmit; Maarten O van Aken; Bas Havekes; Alberto M Pereira; Hanno Pijl; Johannes W Smit; Johannes A Romijn
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-29       Impact factor: 3.478

10.  Progression of hand osteoarthritis over 2 years: a clinical and radiological follow-up study.

Authors:  S Botha-Scheepers; N Riyazi; I Watt; F R Rosendaal; E Slagboom; N Bellamy; F C Breedveld; M Kloppenburg
Journal:  Ann Rheum Dis       Date:  2008-08-26       Impact factor: 19.103

View more
  8 in total

Review 1.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

Review 2.  Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.

Authors:  Evgenia Korytnaya; Ariel Barkan
Journal:  J Neurooncol       Date:  2014-01-18       Impact factor: 4.130

3.  Radiographic features of hand osteoarthritis in adult Kashin-Beck Disease (KBD): the Yongshou KBD study.

Authors:  Q Fu; J Cao; J B Renner; J M Jordan; B Caterson; V Duance; M Luo; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2015-01-24       Impact factor: 6.576

4.  Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity.

Authors:  L M Fatti; B Cangiano; G Vitale; L Persani; G Mantovani; E Sala; M Arosio; P Maffei; F Dassie; M Mormando; A Giampietro; L Tanda; E R Masiello; E Nazzari; D Ferone; S Corbetta; E Passeri; F Guaraldi; S Grottoli; S Cannavò; M L T Torre; D Soranna; A Zambon; F Cavagnini; M Scacchi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 5.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 6.  Towards an Earlier Diagnosis of Acromegaly and Gigantism.

Authors:  Jill Sisco; A J van der Lely
Journal:  J Clin Med       Date:  2021-03-26       Impact factor: 4.241

7.  Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly.

Authors:  Victoria R van Trigt; Iris C M Pelsma; Herman M Kroon; Alberto M Pereira; Coen van der Meulen; Margreet Kloppenburg; Nienke R Biermasz; Kim M J A Claessen
Journal:  Pituitary       Date:  2021-10-23       Impact factor: 4.107

8.  Clinical and radiographic assessment of peripheral joints in controlled acromegaly.

Authors:  Iris C M Pelsma; Herman M Kroon; Victoria R van Trigt; Alberto M Pereira; Margreet Kloppenburg; Nienke R Biermasz; Kim M J A Claessen
Journal:  Pituitary       Date:  2022-06-20       Impact factor: 3.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.